INTRODUCTION {#s1}
============

Ocular melanocytosis is characterized by an excess of melanocytes in the uveal tract, comprising the choroid, ciliary body, and iris, and it has been speculated to represent a congenital nevus ([@MCS004051DURC26]). This condition is usually nonhereditary and unilateral and manifests with brown--gray episcleral patches and dark pigmentation of the ocular fundus, sometimes accompanied by iris heterochromia. When associated with periocular cutaneous hyperpigmentation, it is referred to as nevus of Ota ([@MCS004051DURC22]). Ocular melanocytosis is the strongest predisposing factor for uveal melanoma (UM), increasing its risk from ∼1 in 230,000 to ∼1 in 400 ([@MCS004051DURC20]), and its presence doubles the risk of metastasis from UM ([@MCS004051DURC19]).

UM is the most common primary eye cancer and frequently results in metastatic death ([@MCS004051DURC5]). UM exhibits a distinctive molecular landscape consisting of two mutational "nodes." The first is characterized by mutually exclusive gain-of-function point mutations in members of the Gq signaling pathway (*GNAQ*, *GNA11*, *CYSLTR2*, and *PLCB4*), which trigger constitutive activation of proliferative and survival signals ([@MCS004051DURC23], [@MCS004051DURC24]; [@MCS004051DURC8]; [@MCS004051DURC12]). The second mutational node consists of near--mutually exclusive mutations in the tumor suppressor *BAP1*, the splicing factors *SF3B1*, *SF3A1*, *SRSF2*, *SRSF7*, and *RBM10*, and the translational initiation factor *EIF1AX* ([@MCS004051DURC6], [@MCS004051DURC7]; [@MCS004051DURC11]; [@MCS004051DURC18]; [@MCS004051DURC4]). These "BSE" mutations are prognostically significant and associated with specific chromosomal copy-number aberrations (CNAs) ([@MCS004051DURC4]). Notably, mutations in *BAP1*, located on Chromosome 3p21, are associated with loss of heterozygosity for Chromosome 3 (LOH3), leading to biallelic inactivation of *BAP1* and poor prognosis ([@MCS004051DURC6]).

By the time UMs are detected, the most recent common ancestral tumor clone usually contains a full complement of mutations and CNAs, indicating that these canonical aberrations occur early during tumor evolution ([@MCS004051DURC4]). To determine the order in which these events arise would require an analysis of early precursor lesions, but tissue samples from premalignant uveal nevi are rarely available owing to the delicate location of these lesions within the eye. Here, we describe a patient with ocular melanocytosis who developed UM and was treated by enucleation (eye removal), which provided an invaluable opportunity to interrogate both the tumor and precursor melanocytosis. Next-generation sequencing followed by bioinformatic analysis allowed us to elucidate the early genomic evolutionary events leading to UM.

RESULTS {#s2}
=======

A 56-yr-old white female presented with pain and blurred vision in her left eye, in which the best-corrected visual acuity had dropped to 20/800. External examination revealed diffuse episcleral pigmentation of the left eye ([Fig. 1](#MCS004051DURF1){ref-type="fig"}A), consistent with ocular melanocytosis. Fundus ophthalmoscopic examination showed normal fundus pigmentation in the right eye ([Fig. 1](#MCS004051DURF1){ref-type="fig"}B), in contrast to diffuse fundus hyperpigmentation in the left eye accompanied by a darkly pigmented choroidal tumor ([Fig. 1](#MCS004051DURF1){ref-type="fig"}C). Ultrasonographic examination of the left eye revealed a pedunculated choroidal tumor measuring 14.6 × 14.4 × 7.9 mm, with low internal reflectivity, spontaneous vascular pulsations, and a surrounding exudative retinal detachment, which are typical for UM ([Fig. 1](#MCS004051DURF1){ref-type="fig"}D). Following enucleation, the eye was immediately dissected in the operating room to obtain and snap-freeze samples from the tumor and nontumorous melanocytosis. Histopathological evaluation revealed a marked overabundance of heavily pigmented melanocytes throughout the uveal tract, along with the UM arising from the choroid ([Fig. 1](#MCS004051DURF1){ref-type="fig"}E,F).

![Clinical and pathologic findings in uveal melanoma (UM) associated with ocular melanocytosis. (*A*) Episcleral brown pigmented patches in the left eye, consistent with ocular melanocytosis. (*B*) Color fundus photograph of the normal right eye, (*C*) in contrast to the darkly pigmented fundus (asterisk) and associated UM (arrows) in the left eye. (*D*) B-scan ultrasonography of the UM with associated exudative retinal detachment. (*E*) Enucleated left eye, with dark pigmentation and thickening of the choroid and ciliary body. The region of ocular melanocytosis within the choroid that was sampled for genomic analysis is indicated by the yellow box. (*F*) Histopathologic examination reveals the choroid filled with heavily pigmented melanocytes (arrow) is typical for ocular melanocytosis (hematoxylin & eosin, original magnification 20×). (C) Choroid, (CB) ciliary body, (L) lens, (R) retina, (S) sclera, (T) tumor.](MCS004051Dur_F1){#MCS004051DURF1}

Molecular prognostic testing of the tumor revealed a class 2 GEP, associated with high metastatic risk ([@MCS004051DURC17]). Whole-exome sequencing (WES) followed by mutational analysis revealed a deleterious somatic single-nucleotide alteration (p.D630Y) in *PLCB4* in both the tumor and melanocytosis but not in the blood ([Fig. 2](#MCS004051DURF2){ref-type="fig"}A). An in-frame deletion (p.C320_D311del) that extended into the intronic region was detected in *BAP1* in the tumor but not in the melanocytosis or blood ([Table 1](#MCS004051DURTB1){ref-type="table"}; [Fig. 2](#MCS004051DURF2){ref-type="fig"}A). Analysis of CNAs using WES data revealed loss of Chromosomes 1p, 3, and 9p and gain of Chromosome 8 ([Fig. 2](#MCS004051DURF2){ref-type="fig"}C), all of which were present in the tumor but not the melanocytosis.

![Genomic evolutionary analysis of ocular melanocytosis and associated uveal melanoma. (*A*) Lollipop plots that depict the amino acid changes resulting from the *PLCB4* (p.D630Y) and *BAP1* (p.C320_D311del) mutations in the tumor. (EF) Phosphoinositide-specific phospholipase C domain, (PI-PLC-X) phosphatidylinositol-specific phospholipase C, X domain, (PI-PLC-Y) phosphatidylinositol-specific phospholipase C-Y domain, (C2) C2 domain, (CH) ubiquitin carboxy-terminal hydrolase catalytic domain, (BARD) BRCA1-associated RING domain, (H) HCF1-binding motif, (B) BRCA1-binding domain, (N) nuclear localization sequences. (*B*) Percentage of cells carrying a driver mutation or chromosomal aberration in the ocular melanocytosis versus the tumor. (M) Melanocytosis, (T) tumor. (*C*) Copy-number plots for melanocytosis and tumor samples, respectively, as determined by THetA2. Whereas the melanocytosis showed no copy-number alterations, the tumor showed loss of Chromosomes 1p, 3, and 9p (blue arrowheads) and a smaller subclone with gain of Chromosome 8 (red arrowhead).](MCS004051Dur_F2){#MCS004051DURF2}

###### 

Genomic findings

  ------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene            Genomic location        HGVS cDNA                HGVS protein     Variant type    Variant interpretation  COSMIC ID     Zygosity
  --------- ----------------------------- ------------------------ ---------------- -------------- ------------------------ ------------- --------------
  *PLCB4*    Chromosome 20, NC_000020.10  c.1888G\>T               p.D630Y          Substitution          Pathogenic        COSM1666823   Heterozygous

  *BAP1*     Chromosome 3, NC_000003.11   c.932-8_960\             p.D311_C320del   Deletion              Pathogenic        None          Hemizygous
                                          delTGTCTCAGATGGTGCAGA\                                                                          
                                          GGAGGCGGCTGGTTCATGC                                                                             
  ------------------------------------------------------------------------------------------------------------------------------------------------------

The *PLCB4* mutation was present in slightly less than one-quarter of cells comprising the melanocytosis and in ∼100% of analyzed tumor cells ([Fig. 2](#MCS004051DURF2){ref-type="fig"}B), indicating that it arose within the melanocytosis and that a *PLCB4*-mutant cell gave rise to the UM. LOH3 was absent from the melanocytosis but present in ∼100% of analyzed tumor cells, indicating that it arose early during clonal tumor expansion. By comparison, the *BAP1* mutation was present in about three-quarters and the 8q gain in about one-quarter of the tumor cells. Although limitations in methodology did not allow detailed conclusions regarding genomic evolution, these findings imply that the *BAP1* mutation and 8q gain occurred after LOH3, which is consistent with previous reports ([@MCS004051DURC18]; [@MCS004051DURC4]).

DISCUSSION {#s3}
==========

Gq pathway mutations have been reported in UM, cutaneous blue nevi, and central nervous system melanocytic neoplasms ([@MCS004051DURC10]; [@MCS004051DURC24]; [@MCS004051DURC25]). However, this is the first direct demonstration of a Gq pathway mutation in the nonmalignant uveal tissue giving rise to melanoma in an eye with ocular melanocytosis. Further, it is the first report of a *PLCB4* mutation in any form of ocular or oculodermal melanocytosis. As such, this case is quite distinct from a recent report of cutaneous melanoma arising within nevus of Ota ([@MCS004051DURC25]), which has different demographics and clinical features than ocular melanocytosis. Recently, we identified a second case of ocular melanocytosis in which the nonmalignant uveal tissue harbored a somatic *GNA11* mutation (data not shown), suggesting that Gq pathway mutations may be characteristic of this condition. This oncogenic "first hit" mutation could explain the increased risk of UM associated with ocular melanocytosis and confirms that this condition represents a congenital nevus rather than simply an excess of normal melanocytes. The absence of a germline mutation is consistent with the lack of hereditary transmission in most patients with this condition.

We recently analyzed 151 primary UMs and showed that all of the canonical mutations and CNAs usually arose early in tumor evolution, making it difficult to discriminate the relative order in which these aberrations accrued ([@MCS004051DURC4]). This case allowed a more detailed exploration into the evolutionary dynamics of UM ([Fig. 3](#MCS004051DURF3){ref-type="fig"}). The *PLCB4* mutation in the precursor melanocytosis was clearly the initiating event but could not effectuate malignant transformation without additional aberrations. This finding is particularly interesting because mutant GNAQ signals to PKC through PLCβ and thereby activates the MAPK pathway ([@MCS004051DURC2]). The earliest events specific to the tumor were loss of Chromosomes 1p, 3, and 9p, which were present in virtually all tumor cells. Additionally, by producing haploinsufficiency for *BAP1*, LOH3 may have created a selective pressure to inactivate the other *BAP1* allele, a requisite event for conversion to the highly metastatic class 2 GEP ([@MCS004051DURC6]; [@MCS004051DURC17]). Thus, LOH3 could represent a "threshold" event in malignant transformation. Gain of 8q was a late event and, hence, apparently not required for malignant transformation but likely providing a selective advantage during tumor progression.

![Qualitative tumor evolution diagram of ocular melanocytosis giving risk to UM. The proposed genomic evolution from melanocytosis to UM, in this case, is presented. The Gq pathway mutation (*PLCB4*) was the earliest event, arising in the ocular melanocytosis and present in all tumor cells. Loss of heterozygosity for Chromosome 3 (LOH3) was absent from the melanocytosis but present in all tumor cells, and it was followed by mutation of *BAP1* on the other copy of Chromosome 3. These events resulting in biallelic *BAP1* deficiency occurred close in evolutionary time and may represent a threshold event in malignant transformation by converting the tumor to the high metastatic risk class 2 gene expression profile (GEP). A small subclone of Chromosome 8 gain is also observed and depicted as arising from the *BAP1* subclone, although it could also have arisen in a separate subclone. For clarity, the loss of Chromosomes 1p and 9p is not included in the diagram.](MCS004051Dur_F3){#MCS004051DURF3}

These insights may help to address persistent challenges in the field. For example, the failure of targeted therapies aimed at inhibiting the Gq pathway ([@MCS004051DURC1]) might be explained by the inability of these mutations to drive malignant tumor growth without additional genomic aberrations. Further, some UMs with good prognosis exhibit LOH3 yet retain a wild-type *BAP1* allele and class 1 GEP ([@MCS004051DURC17]; [@MCS004051DURC4]), suggesting that biallelic loss of *BAP1* is required for conversion to the class 2 GEP and that LOH3 alone is insufficient to confer high metastatic risk.

METHODS {#s4}
=======

Sample Collection {#s4a}
-----------------

Tissue samples were subjected to DNA extraction using the Wizard Genomic DNA Purification kit (Promega) and RNA extraction using the PicoPure RNA Isolation kit (Thermo Fisher Scientific). DNA from peripheral blood leukocytes was extracted using the QuickGene DNA whole blood kit S (Fujifilm).

Whole-Exome Sequencing and Validation {#s4b}
-------------------------------------

WES was performed as previously described ([@MCS004051DURC4]), using the Agilent SureSelect XT Human All Exon V5 kit with 100-bp paired-end sequencing on the Illumina HiSeq 2500 sequencer ([Table 2](#MCS004051DURTB2){ref-type="table"}). WES mutation results were validated using the DecisionDx-UMseq targeted next-generation sequencing panel (Castle Biosciences, Inc.). Molecular prognostic classification of the tumor was performed by GEP as part of routine clinical management using the DecisionDx-UM test (Castle Biosciences, Inc.). The GEP test uses a 15-gene PCR assay comprising of 12 discriminating genes, two control genes, and expression of *PRAME*, a gene that provides independent prognostic information. This test can be performed on fine-needle aspirate biopsy samples and stratifies UM patients in the low-, intermediate-, and high-risk groups ([@MCS004051DURC16]).

###### 

Whole-exome sequencing metrics

                                                  Blood         Melanocytosis   Tumor
  ----------------------------------------------- ------------- --------------- -------------
  Mean depth of coverage                          78×           56×             56×
  Percentage of exome with at least 1× coverage   100%          99%             99%
  Depth of coverage at reported *PLCB4* variant   N/A           83×             178×
  Depth of coverage at reported *BAP1* variant    N/A           N/A             30×
  Total reads                                     100,666,026   80,33,8148      164,244,502
  Total mapped reads                              97,070,265    77,365,636      156,225,641

(N/A) Not applicable.

Bioinformatic Analysis {#s4c}
----------------------

FASTQ files containing WES data were subjected to quality control using FASTQC (v0.11.3), trimmed and aligned to the human genome build hg19/GRCH37 using Novoalign (v3.04.06), marked for duplicates using Picard (v1.128), realigned around small and large indels using ABRA (v0.94c) ([@MCS004051DURC13]), and then read mate fixed and analyzed for coverage statistics using Picard. Variant calling for SNPs and indels was performed using MuTect2 (GATK 2016-01-25 nightly build) ([@MCS004051DURC3]) comparing the tumor and melanocytosis regions to matched blood. Lollipop plots were generated using MutationMapper (<http://www.cbioportal.org/mutation_mapper.jsp>), and domain information was annotated from a previous publication ([@MCS004051DURC4]). CNAs were assessed from WES data using CNVKit (v0.7.5, v0.7.10.dev0) ([@MCS004051DURC21]) and b-allele frequency plots were assessed from WES using THetA2 (v0.7) ([@MCS004051DURC15]). Clonality of CNAs was assessed using cgpBattenberg, as previously described ([@MCS004051DURC14]; [@MCS004051DURC4]), and depicted using a qualitative tumor clone evolution diagram ([@MCS004051DURC9]).

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

All sequencing data generated have been deposited in dbGaP (<https://www.ncbi.nlm.nih.gov/gap>) under accession code phs001835.v1.p1. The reported variants were submitted to ClinVar (<https://ncbi.nlm.nih.gov/clinvar/>) and can be found under accession numbers SCV000920585 and SCV000920586.
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